CD10 Expression in Bladder Urothelial Carcinoma is Linked to Both High Tumor Grade and Late Stage

Basit Öğe Kaydı
dc.contributor.authorDevrim, Tuba
dc.date.accessioned2025-03-21T07:37:55Z
dc.date.available2025-03-21T07:37:55Z
dc.date.issued2024
dc.departmentİzmir Bakırçay Üniversitesi
dc.description.abstractObjective. Bladder urothelial carcinoma continues to be a vital problem despite developing treatment options and constitutes a patient group that requires close follow-up with a high recurrence rate. Bladder cancer recurrence following initial resection in patients with pTa and pT1 tumors can reach rates as elevated as 80%. This study aims to examine CD10 immunohistochemical expression in urothelial carcinoma of the bladder and evaluate its relationship with histopathological parameters. Material and Method. 56 urothelial carcinoma cases taken from the bladder were included in our study. Histopathologically, hematoxylin-eosin (HE) stained sections of each case were re-evaluated and classified according to the current WHO grading system. Within the scope of the study, 57.4% of the cases were high-grade and 42.9% were low-grade urothelial carcinoma. Results. Positive CD10 expression was detected in 80.4% of cases. A significant correlation was found between CD10 expression and tumor invasion and high histological grade (p˂0.001). Significantly higher CD10 expression was detected in invasive pT1, pT2, and pT3 tumors compared to non-invasive pTa tumors (p=0.003; 0.004, and 0.01, respectively). A significant positive correlation was also found between pT and CD10 (r = 0.43, p = 0.001). No relationship was found between CD10 immunoexpression and overall survival, disease-free survival, and other clinicopathological criteria. Conclusion. The analysis revealed a robust correlation between CD10 expression and high tumor grade, invasion, and pathological stage in urothelial carcinoma of the bladder. Considering these collective findings, it was deduced that CD10 might play a role in tumor progression within the pathogenesis of bladder cancer. Key Words: Bladder, Urothelial carcinoma, Immunohistochemistry, CD10
dc.description.sponsorshipSüleyman Demirel Üniversitesi
dc.identifier.doi10.22312/sdusbed.1471574
dc.identifier.doihttps://doi.org/10.22312/sdusbed.1471574
dc.identifier.endpage415
dc.identifier.issn2146-247X
dc.identifier.issue3
dc.identifier.startpage410
dc.identifier.urihttps://hdl.handle.net/20.500.14034/2582
dc.identifier.volume15
dc.institutionauthorDevrim, Tuba
dc.language.isoen
dc.publisherSüleyman Demirel University
dc.relation.ispartofSüleyman Demirel Üniversitesi Sağlık Bilimleri Dergisi
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_DergiPark_20250319
dc.subjectBladder
dc.subjectUrothelial carcinoma
dc.subjectImmunohistochemistry
dc.subjectCD10
dc.titleCD10 Expression in Bladder Urothelial Carcinoma is Linked to Both High Tumor Grade and Late Stage
dc.title.alternativeCD10 Expression in Bladder Urothelial Carcinoma is Linked to Both High Tumor Grade and Advanced Stage
dc.typeArticle

Dosyalar

Koleksiyon

Öksüz Yayınları